Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

ClinicalTrials.gov ID: NCT07645248

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07645248. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, 2-way Crossover, Multicenter Study to Evaluate the Safety of Test Propellant HFA-152a and Reference Propellant HFA-134a When Administered Via Metered Dose Inhalers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).

Study identification

NCT ID
NCT07645248
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
110 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 1, 2026 (Actual)
Primary completion
Dec 28, 2026 (Estimated)
Completion
Dec 28, 2026 (Estimated)
Last update posted
Nov 5, 2026

2026

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
GSK Investigational Site Aventura Florida 33180 Recruiting
GSK Investigational Site Miami Florida 33155 Recruiting
GSK Investigational Site Miami Florida 33173-3484 Recruiting
GSK Investigational Site Naples Florida 34102 Recruiting
GSK Investigational Site Owensboro Kentucky 42301 Recruiting
GSK Investigational Site Columbia Missouri 65203 Recruiting
GSK Investigational Site Henderson Nevada 89052-5015 Recruiting
GSK Investigational Site Medford Oregon 97504 Recruiting
GSK Investigational Site Spartanburg South Carolina 29303-4225 Recruiting
GSK Investigational Site Spartanburg South Carolina 29303 Recruiting
GSK Investigational Site Cypress Texas 77429 Recruiting
GSK Investigational Site Tomball Texas 77375 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07645248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 5, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.